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Predicting Lymph Node Metastasis in
Non-small Cell Lung Cancer
Prospective External and Temporal Validation of the HAL and
HOMER Models
Gabriela Martinez-Zayas, MD; Francisco A. Almeida, MD; Lonny Yarmus, DO; Daniel Steinfort, PhD;
Donald R. Lazarus, MD; Michael J. Simoff, MD; Timothy Saettele, MD; Septimiu Murgu, MD; Tarek Dammad, MD;
D. Kevin Duong, DO; Lakshmi Mudambi, MD; Joshua J. Filner, MD; Soﬁa Molina, MD; Carlos Aravena, MD;
Jeffrey Thiboutot, MD; Asha Bonney, MD; Adriana M. Rueda, MD; Labib G. Debiane, MD; D. Kyle Hogarth, MD;
Harmeet Bedi, MD; Mark Deffebach, MD; Ala-Eddin S. Sagar, MD; Joseph Cicenia, MD; Diana H. Yu, MD; Avi Cohen, MD;
Laura Frye, MD; Horiana B. Grosu, MD, MPH; Thomas Gildea, MD; David Feller-Kopman, MD; Roberto F. Casal, MD;
Michael Machuzak, MD; Muhammad H. Arain, MBBS; Sonali Sethi, MD; George A. Eapen, MD; Louis Lam, MD;
Carlos A. Jimenez, MD; Manuel Ribeiro, MD; Laila Z. Noor, MD; Atul Mehta, MD; Juhee Song, PhD; Humberto Choi, MD;
Junsheng Ma, PhD; Liang Li, PhD; and David E. Ost, MD, MPH

Two models, the Help with the Assessment of Adenopathy in Lung cancer
(HAL) and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER), were
recently developed to estimate the probability of nodal disease in patients with non-small cell
lung cancer (NSCLC) as determined by endobronchial ultrasound-transbronchial needle
aspiration (EBUS-TBNA). The objective of this study was to prospectively externally validate
both models at multiple centers.

BACKGROUND:

RESEARCH QUESTION:

Are the HAL and HOMER models valid across multiple centers?

This multicenter prospective observational cohort study
enrolled consecutive patients with PET-CT clinical-radiographic stages T1-3, N0-3, M0
NSCLC undergoing EBUS-TBNA staging. HOMER was used to predict the probability of N0
vs N1 vs N2 or N3 (N2j3) disease, and HAL was used to predict the probability of N2j3 (vs
N0 or N1) disease. Model discrimination was assessed using the area under the receiver
operating characteristics curve (ROC-AUC), and calibration was assessed using the Brier
score, calibration plots, and the Hosmer-Lemeshow test.
STUDY DESIGN AND METHODS:

RESULTS: Thirteen centers enrolled 1,799 patients. HAL and HOMER demonstrated good
discrimination: HAL ROC-AUC ¼ 0.873 (95%CI, 0.856-0.891) and HOMER ROC-AUC ¼
0.837 (95%CI, 0.814-0.859) for predicting N1 disease or higher (N1j2j3) and 0.876 (95%CI,
0.855-0.897) for predicting N2j3 disease. Brier scores were 0.117 and 0.349, respectively.
Calibration plots demonstrated good calibration for both models. For HAL, the difference

ABBREVIATIONS: CHEST = American College of Chest Physicians;
EBUS-TBNA = endobronchial ultrasound-transbronchial needle aspiration; ESTS = European Society of Thoracic Surgery; HAL = acronym
to the Help with the Assessment of Adenopathy in Lung cancer model;
HOMER = acronym to the Help with Oncologic Mediastinal Evaluation for Radiation model; NCCN = National Comprehensive Cancer
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Network; NSCLC = non-small cell lung cancer; ROC-AUC = area
under the receiver operating characteristics curve; SABR = stereotactic
ablative radiotherapy; SPN = solitary pulmonary nodule
AFFILIATIONS: From the Department of Pulmonary Medicine (G.
Martinez-Zayas, S. Molina, H. B. Grosu, R. F. Casal, M. H. Arain, G. A.
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between forecast and observed probability of N2j3 disease was þ0.012; for
HOMER, the difference for N1j2j3 was 0.018 and for N2j3 was þ0.002. The
Hosmer-Lemeshow test was signiﬁcant for both models (P ¼ .034 and .002),
indicating a small but statistically signiﬁcant calibration error.
HAL and HOMER demonstrated good discrimination and calibration in
multiple centers. Although calibration error was present, the magnitude of the error is small,
such that the models are informative.
CHEST 2021; 160(3):1108-1120

INTERPRETATION:

KEY WORDS:

endobronchial ultrasound; lung cancer; lung cancer staging; mediastinal

adenopathy

Correct mediastinal staging is critical for decisionmaking in non-small cell lung cancer (NSCLC) because
treatment options and prognosis vary according to
stage.1 Surgical resection with mediastinal lymph node
dissection is warranted for patients without nodal
involvement (N0) and for select patients with ipsilateral
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hilar nodal involvement (T1-2, N1).2 For patients that
cannot tolerate surgery because of comorbidities and
those who refuse surgery, stereotactic ablative
radiotherapy (SABR) may be an option, provided there
is no mediastinal or hilar node involvement.3 Once
mediastinal lymph nodes are involved, multimodality
treatment with chemotherapy, radiation, or targeted
therapy is usual.4
Because lymph node involvement markedly impacts
treatment decisions, the diagnostic approach to NSCLC
revolves around assessment of the probability of lymph
node involvement.5-7 Current American College of
Chest Physicians (CHEST) and National
Comprehensive Cancer Network (NCCN) guidelines
suggest using PET-CT to look for evidence of lymph
node metastasis.1,8 In patients with a sufﬁciently high
probability of nodal metastasis, mediastinal lymph node
sampling with a needle technique such as endobronchial
ultrasound guided-transbronchial needle aspiration
(EBUS-TBNA) is warranted.6 However, determining the
probability of nodal disease is difﬁcult because PET-CT,
while useful, has limited sensitivity and speciﬁcity for
nodal involvement.1,6
The CHEST and NCCN guidelines have suggested using
prediction models to estimate the probability of cancer
to manage solitary pulmonary nodules (SPNs).6,8,9
Similarly, models exist to estimate the probability of
nodal disease in patients with NSCLC, with varying
success.10-17 Recently, the Help with the Assessment of
Adenopathy in Lung cancer (HAL)10 and Help with
Oncologic Mediastinal Evaluation for Radiation
(HOMER)17 models were developed retrospectively and
externally validated on three retrospective independent
datasets. HAL is a binary logistic regression model,
which predicts the probability of N0 or N1 disease
(prN0j1) vs the probability of N2 or N3 disease (prN2j3)
as determined by EBUS-TBNA.10 HOMER is an ordinal
logistic regression model that predicts prN0 vs prN1
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Take-home Points
Study Question: Are the HAL and HOMER models
for predicting malignant mediastinal lymph node
involvement valid across multiple centers?
Results: HAL and HOMER demonstrated good
discrimination (ROC $ 0.83) in 1,799 patients across
13 centers, and they demonstrated good calibration
between forecast and observed probabilities of nodal
disease (difference, þ0.012 for HAL and 0.018
and þ0.002 for HOMER).
Interpretation: In multiple centers, HAL and
HOMER demonstrated good discrimination and
calibration.

Study Design and Methods
This multicenter international prospective observational cohort study
involved 13 different hospitals. All consecutive patients with
untreated PET-CT clinical radiographic stage T1-3, N0-3, M0
NSCLC that underwent EBUS-TBNA staging were included. Patients
who had CT-proven mediastinal invasion, distant metastases,
synchronous primaries, recurrent disease, or small cell lung cancer
were excluded (e-Table 1).10,17 The study was approved by the
Institutional Review Board, Committee 4, Protocol PA16-0107 at the
University of Texas MD Anderson on June 10, 2016, and enrollment
closed on March 1, 2019 (e-Appendix 1).
All variable deﬁnitions were developed before data abstraction,
provided to all sites, and are identical to previously published
criteria for HAL and HOMER (see e-Appendix 1, Methods, for
further details).10,17 PET-CT was used to deﬁne N stage and tumor
location (central vs peripheral), using previously established
deﬁnitions.10,17-19 Lymph node N stage was based on the radiology
report and supplemented by interventional pulmonologist review.
CT N stage was based on the enlargement of lymph nodes
to $1 cm on their short-axis diameter. PET N stage was based on
the radiologist’s assessment of ﬂuorodeoxyglucose avidity in
mediastinal and hilar lymph nodes. Radiographic N stage by PET
and by CT were deﬁned as the highest abnormal nodal station using
The Eighth Edition Lung Cancer Stage Classiﬁcation.20 Central
tumors were deﬁned as those in the inner one third of the
hemithorax (e-Fig 1).19
The predicted outcome variable was the presence of nodal involvement
as determined by EBUS-TBNA. All EBUS-TBNA procedures used a
systematic approach, deﬁned as sampling of N3 nodes ﬁrst, then N2
nodes, and ﬁnally N1 nodes.21 All lymph nodes $ 0.5 cm by EBUS
were sampled, independent of PET-CT status.21

Statistical Analysis
Prediction Models
HAL was used to calculate the predicted probability of the highest
nodal station with malignant lymph node involvement for each
patient. Highest nodal stage was determined by EBUS-TBNA and
dichotomized as N0j1 vs N2j3 disease10 (Table 1).
HOMER was used to calculate the predicted probability of the
highest nodal station with malignant lymph node involvement for
each patient. Highest nodal stage was determined by EBUS-TBNA
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vs prN2j3 as determined by EBUS-TBNA.17 HOMER
performed well over long periods at the model
development institution17 (ie, temporal validation), but
performance over time was not measured at other
hospitals. HAL has not been temporally validated at any
site.
The objective of this study was to prospectively and
externally validate HAL and HOMER at multiple new
centers to determine whether these clinical prediction
rules are suitable for generalized clinical use. The
secondary objective was to temporally validate HAL (at
the model development and external validation
institutions) and HOMER (at the external validation
institutions).
and was categorized in an ordinal fashion as N0 vs N1 vs N2j3.17
Because HOMER is an ordinal logistic regression model with
three possible outcomes, two formulas constitute the model, one
to predict the probability of N1 disease or higher (prN1j2j3) and
another to predict prN2j3 (Table 1).
Temporal and External Validation
For HAL validation, prospective data from 13 hospitals (nine new plus
original institutions) were used. For HOMER validation, prospective
data from 12 hospitals (nine new plus original external validation
institutions) were used, because the previously published temporal
validation of HOMER used a portion of the model development
institution data.17
Assessment of Model Performance
Model performance was assessed for discrimination using the area
under the receiver operating characteristics (ROC) curve (AUC).
Calibration was assessed using the Hosmer-Lemeshow goodness-of-ﬁt
test, Brier scores, and observed vs predicted graphs. We prespeciﬁed
that the primary analysis would assess model performance for the
entire cohort, and a secondary analysis would assess model
performance stratiﬁed by institution.
Exploratory Analyses
Hospital-level variables have previously been shown to impact
bronchoscopic diagnostic yield22,23 and might impact outcome and
model performance. We used random effects models to test for
center-level effects (e-Appendix 1).
In the previously published HAL and HOMER reports, model
discrimination was good in all centers, but calibration was off in two
centers.10,17 In those studies, institution-speciﬁc calibrated models
were created (e-Table 2).10,17,24 We performed an exploratory
analysis to temporally validate the calibrated models at their
respective institutions (e-Appendix 1).
Sample Size
For the entire cohort, sample size was calculated so that the lower
bound of the 95% CI for ROC-AUC would be 0.70 or higher. We
chose the threshold value of 0.70 based on currently used clinical
prediction models for SPNs (e-Table 3).25 The rationale was that if
the ROC-AUC lower limit of the 95% CI was 0.70 or greater and
calibration was sufﬁcient, then the model would potentially be
clinically useful. Based on prior data and conservative assumptions,
we estimated the ROC-AUC would be 0.73 and the prevalence of
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TABLE 1

] HAL and HOMER Prediction Formulas

Probability Being Predicted

HAL Model Formula

Predicted prN2|3 using HAL

expðAÞ
prN2 3 ¼
where A ¼  1:0663  0:0311  ðage of patientÞ þ
1 þ expðAÞ
0:5881  Iðtumor location ¼ central third of the lungÞ  0:8235  Iðtumor histology ¼
squamous cell carcinomaÞ þ 0:1423  IðNonsmall cell lung carcinomaÞ  0:5079 
Iðother primary lung cancerÞ þ 0:9694  IðCT ¼ N2j3; PET ¼ N0Þ þ 1:5766  IðCT ¼
N0jN1; PET ¼ N1Þ þ 0:9009  IðCT ¼ N2jN3; PET ¼ N1Þ þ 2:3726  IðCT ¼
N0j1; PET ¼ N2j3Þ þ 3:7531  IðCT ¼ N2j3; PET ¼ N2j3Þ

Probability being predicted

HOMER Model formula

Predicted prN1|2|3 using
HOMER

prN1j2j3 ¼

Predicted prN2|3 using HOMER

Predicted prN0 and prN1
derived from HOMER

expðBÞ
where B ¼  0:89  0:0292  ðage of the patientÞ þ 0:4864 
1 þ expðBÞ
Iðtumor location ¼ central third of the lungÞ  0:8217  Iðtumor histology ¼
squamous cell carcinomaÞ þ 0:0635  Iðtumor histology ¼
nonsmall cell lung carcinomaÞ  0:4097  Iðtumor histology ¼
other primary lung cancerÞ þ 1:1738  IðCT ¼ N2j3; PET ¼ N0Þ þ 3:0832  IðCT ¼
N0j1; PET ¼ N1Þ þ 2:9905  IðCT ¼ N2j3; PET ¼ N1Þ þ 2:2595  IðCT ¼ N0j1; PET ¼
N2j3Þ þ 3:7113  IðCT ¼ N2j3; PET ¼ N2j3Þ
expðCÞ
where C ¼  1:1576  0:0292  ðage of the patientÞ þ 0:4864 
1 þ expðCÞ
Iðtumor ¼ centralof third the lungÞ  0:8217  Iðtumor histology ¼
squamous cell carcinomaÞ þ 0:0635  Iðtumor histology ¼
nonsmall cell lung carcinomaÞ  0:4097  Iðtumor histology ¼
other primary lung cancerÞ þ 0:9798  IðCT ¼ N2j3; PET ¼ N0Þ þ 1:5937  IðCT ¼
N0j1; PET ¼ N1Þ þ 0:9323  IðCT ¼ N2j3; PET ¼ N1Þ þ 2:3599  IðCT ¼ N0j1; PET ¼
N2j3Þ þ 3:7486  IðCT ¼ N2j3; PET ¼ N2j3Þ

prN2 3 ¼

Using HOMER, it follows that prN0 ¼ 1  prN1j2j3 and prN1 ¼ prN1j2j3  prN2j3:

I(X) is an indicator function and equals 1 if X is true, otherwise equals 0. exp(A) ¼ exponential or base of the natural logarithm of A; exp(B) ¼ exponential or
base of the natural logarithm of B; exp(C) ¼ exponential of base of the natural logarithm of C; prN0 ¼ probability of N0 disease; prN1 ¼ probability of N1
disease; prN1|2|3 ¼ probability of N1 disease or higher; prN2|3 ¼ probability of N2 or N3 disease.

N2j3 disease would be 23%, which resulted in a sample size of 1,252
patients (e-Appendix 1).26 For the secondary analysis stratiﬁed by
institution, we estimated that 100 patients per institution would
provide precise calibration estimators and that 50 patients per
institution would be sufﬁcient to obtain a stable ROC-AUC for that
center. Therefore, we prespeciﬁed that centers with fewer than 100
patients would be excluded from institution-level calibration
assessment, and those with fewer than 50 patients would be excluded

from institution-level discrimination assessment, because estimates
would be unreliable (see e-Appendix 1 for details). We therefore
decided to enroll a minimum of 1,300 consecutive patients across 13
centers. Institutions were allowed to enroll more than 100 patients,
but the goal was to have as many institutions reach the 100-patient
threshold as possible.

Results

(0.117) was good. However, the Hosmer-Lemeshow P
value was signiﬁcant (P ¼ .034). The forecast
vs observed prN2j3 disease was 0.251 and 0.239,
respectively. Although the small Hosmer-Lemeshow P
value suggests lack of calibration beyond random
variation, the absolute magnitude of the calibration error
is small (see Fig 2 and Brier scores) and may not be
consequential from a clinical perspective; also, the
impact of lack of calibration depends on the clinical
context.27

A total of 1,799 patients in 13 hospitals with clinicalradiographic T1-3, N0-3, M0 NSCLC as determined by
PET-CT who underwent EBUS-TBNA were enrolled
(Table 2).
Prospective External and Temporal Validation of
HAL for Predicting N0j1 vs N2j3 Disease

Clinical characteristics according to nodal status (N0j1
vs N2j3) are shown in e-Table 4. Predictions using HAL
demonstrated good discrimination and calibration in the
validation cohort (n ¼ 1,799). ROC-AUC was 0.873
(95% CI, 0.856-0.891; Fig 1A). Calibration as assessed by
observed vs predicted plots (Fig 2A) and Brier score

chestjournal.org

All statistical analyses used SAS 9.4, STATA 15.1, and R 3.5.1.

Three centers enrolled fewer than 50 patients per
center (total n ¼ 98). Excluding these patients from
the combined analysis did not signiﬁcantly impact
discrimination (n ¼ 1,701, ROC-AUC ¼ 0.875; Fig

1111

] Enrolled Patients Across 13 Different Hospitals

TABLE 2

Overall (N ¼ 2,127)

Variable

Excluded (n ¼ 328)

Included (n ¼ 1,799)

Institution, No. (%)
Christus St. Vincent Santa Fea
Cleveland Clinic Foundation
Henry Ford Hospital
Michael E. DeBakey Hospital
Johns Hopkins
Kaiser Permanentea
MD Anderson Cancer Center
Royal Melbourne Hospital
VA Portland Healthcare System
St. Luke’s of Kansas City
Stanford University

38 (1.8)

5 (1.7)

33 (1.8)

361 (17.0)

53 (13.0)

308 (17.6)

112 (5.3)

4 (1.4)

108 (5.9)

117 (5.5)

0 (0.0)

117 (6.4)

239 (11.2)

46 (15.8)

193 (10.5)

51 (2.4)

17 (5.8)

34 (1.9)

679 (31.9)

124 (37.7)

555 (30.8)

146 (6.9)

13 (4.5)

133 (7.2)

61 (2.9)

7 (1.4)

54 (3.1)

103 (4.8)

1 (0.3)

102 (5.6)

67 (3.1)

3 (0.3)

64 (3.6)

University of Chicago

85 (4.0)

18 (5.8)

67 (3.7)

University of New Mexicoa

68 (3.2)

37 (12.3)

31 (1.7)

a

Institutions with fewer than 50 patients that were included for the combined cohort analysis but excluded from the stratiﬁed by institution analysis. The
reasons of patients’ exclusion are found in e-Table 1.

1B) or calibration (Brier score, 0.112; HosmerLemeshow P ¼ .675; forecast prN2j3 disease ¼
0.242, observed prN2j3 ¼ 0.220). The HosmerLemeshow P value is dependent on sample size.
Therefore, an increase in P value with reduced
sample size does not necessarily imply better
calibration.27
Model performance stratiﬁed by institution is provided
in Table 3. Discrimination on a per-hospital basis
remained good, with ROC-AUC ranging from 0.810 to
0.917 and Brier scores from 0.083 to 0.141.

A

Exploratory testing demonstrated presence of centerlevel effects. The random effects model using a random
intercept is provided in e-Appendix 1. Although it did
outperform the baseline HAL model (P < .001), the
absolute magnitude of discrimination improvement was
small (ROC-AUC improved from 0.873 to 0.887).
Details of the exploratory analysis comparing the
previously published institution-speciﬁc calibrated
models are summarized in e-Table 5. The baseline HAL
model outperformed the institution-speciﬁc calibrated
HAL models in every institution (e-Appendix 1).

B

1.00

0.75
Sensitivity

0.75
Sensitivity

1.00

0.50

0.50

0.25

0.25

0.00

0.00
0.00

0.25

0.50
1 - Specificity

0.75

1.00

0.25

0.00

0.50
1 - Specificity

0.75

1.00

Figure 1 – Receiver operating characteristic curves of the HAL model in the combined validation cohort. The ﬁgure plots the area under the curve
(AUC) for A, N2 or N3 (vs N0 or N1) disease (AUC ¼ 0.873) for all patients that met inclusion criteria from all 13 institutions (n ¼ 1,799), and for B,
N2 or N3 (vs N0 or N1) disease (AUC ¼ 0.875) for patients that met inclusion criteria from institutions that had more than 50 eligible patients (n ¼
1,701). HAL ¼ Help with the Assessment of Adenopathy in Lung cancer model.
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A

B
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0.00
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Figure 2 – Observed vs predicted plots for the HAL model in the combined validation cohort for A, all patients that met inclusion criteria from all 13
institutions (n ¼ 1,799) and B, for patients that met inclusion criteria from institutions that had more than 50 eligible patients (n ¼ 1,701). The ﬁgure
plots the probability of N2 or N3 (vs N0 or N1) disease by decile of expected risk as a function of the actual observed risk in that group. The observed
probability for each decile is on the vertical axis; the predicted probability for each decile is on the horizontal axis. A perfect model, where observed ¼
predicted, is shown by the line. HAL ¼ Help with the Assessment of Adenopathy in Lung cancer model.

Prospective External and Temporal Validation of
HOMER for Predicting N0 vs N1 vs N2j3 Disease

Clinical characteristics according to nodal status (N0
vs N1 vs N2j3) are shown in e-Table 6. Predictions using
TABLE 3

HOMER demonstrated good discrimination and
calibration in the validation cohort (n ¼ 1,244). ROCAUC was 0.837 (95% CI, 0.814-0.859; Fig 3A) for
predicting prN1j2j3 (vs prN0) disease and 0.876

] HAL Model Performance at Different Institutions
ROC-AUC (95% CI)

Brier
Score

Observed prN2|3
(vs N0|1)

Forecast prN2|3
(vs N0|1)

Entire cohort (n ¼ 1,799)

0.873 (0.856-0.891)

0.117

0.239

0.251

.034

Cohort excluding centers with <50
patients (n ¼ 1,701)

0.875 (0.856-0.894)

0.112

0.220

0.242

.675

MD Anderson Cancer Centera
(n ¼ 555)

0.871 (0.835-0.949)

0.109

0.193

0.228

.0467

Cleveland Clinic Foundationb
(n ¼ 308)

0.913 (0.880-0.945)

0.092

0.182

0.216

.704

Henry Ford Hospitalb (n ¼ 108)

0.848 (0.772-0.924)

0.136

0.269

0.290

.293

Johns Hopkins (n ¼ 193)

0.838 (0.776-0.899)

0.141

0.285

0.304

.280

Royal Melbourne Hospitalc (n ¼ 133)

0.917 (0.862-0.973)

0.110

0.338

0.230

.010

0.912 (0.847-0.977)

0.083

0.188

0.165

.768

0.887 (0.813-0.962)

0.120

0.245

0.204

.459

0.909 (0.828-0.990)

NA

NA

NA

NA

Stanford Universityc (n ¼ 64)

0.839 (0.742-0.937)

NA

NA

NA

NA

University of Chicagoc (n ¼ 67)

0.810 (0.692-0.989)

NA

NA

NA

NA

Population

b

Michael E. DeBakey VA Hospital
(n ¼ 117)

c

St. Luke’s of Kansas Cityc (n ¼ 102)
VA Portland Healthcare System
(n ¼ 54)

c

HosmerLemeshow P

Brier scores range from 0 (perfect) to 1 (worst) for a binary outcome. EBUS-TBNA ¼ endobronchial ultrasound guided-transbronchial needle aspiration;
NA ¼ Not applicable because enrollment did not reach the required n $ 100 for these centers; N0|1 ¼ N0 or N1; prN2|3 ¼ probability of N2 or N3 disease;
ROC-AUC ¼ area under the receiver operator characteristic curve.
a
Hospital where HAL was developed; data tests temporal validation.
b
Hospital where HAL was previously tested; new data tests temporal external validation of HAL.
c
Hospital where HAL was never tested before; external validation of HAL
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Figure 3 – Receiver operating characteristic curves of the HOMER model in the combined validation cohort. The ﬁgure plots the area under the curve
(AUC) for A, N1 or higher (vs N0) disease (AUC ¼ 0.837) and B, N2 or N3 (vs N0 or N1) disease (AUC ¼ 0.876) for all patients that met inclusion
criteria from all non-MDACC institutions (n ¼ 1,244), and for C, N1 or higher (vs N0) disease (AUC ¼ 0.837) and D, N2 or N3 (vs N0 or N1) disease
(AUC ¼ 0.878) for patients that met inclusion criteria from non-MDACC institutions that had more than 50 eligible patients (n ¼ 1,146). HOMER ¼
Help with Oncologic Mediastinal Evaluation for Radiation; MDACC ¼ MD Anderson Cancer Center.

(95% CI, 0.855-0.897; Fig 3B) for predicting prN2j3 (vs
prN0j1) disease. Calibration as assessed by observed
vs predicted plots (Figs 4A, 4B) and Brier score (0.349)
was good. However, the Hosmer-Lemeshow P value was
signiﬁcant (P ¼ .002). The forecast vs observed prN1j2j3
disease was 0.339 and 0.357, respectively. The forecast
vs observed prN2j3 disease was 0.261 and 0.259,
respectively.
Excluding centers that enrolled fewer than 50 patients
did not signiﬁcantly change discrimination for prN1j2j3
(n ¼ 1,146; ROC-AUC ¼ 0.837; Fig 3C) and prN2j3
(ROC-AUC ¼ 0.878, Fig 3D), or calibration (Brier score,
0.341; Hosmer-Lemeshow P < .001; observed
vs predicted plots, Figs 4C and 4D, forecast prN1j2j3
vs observed prN1j2j3 was 0.325 and 0.335, respectively,
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and forecast prN2j3 disease vs observed prN2j3 was
0.249 and 0.233, respectively).
Model performance stratiﬁed by institution
demonstrated good discrimination in eight of nine
hospitals, with ROC-AUC ranging from 0.711 to 0.912
(Table 4) for prN1j2j3 (vs N0) disease, and diminished
discrimination in one hospital (ROC-AUC ¼ 0.672;
Table 4). Discrimination was good in all hospitals for
prN2j3 (vs N0j1) disease, with ROC-AUC ranging from
0.809 to 0.919 (Table 4). Calibration on a per-hospital
basis was similar, with Brier scores ranging from 0.283
to 0.370 (Table 4).
Exploratory testing using a random effects model
demonstrated the presence of center-level effects (eAppendix 1). Although the random effects model did
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Figure 4 – Observed vs predicted plots for the HOMER model in the combined validation cohort. The ﬁgure plots the probability of N1 or higher (vs N0)
disease for A and the probability (B) of N2 or N3 (vs N0 or N1) disease by decile of expected risk for all patients that met inclusion criteria from all nonMDACC institutions (n ¼ 1,244) and the probability of (C) N1 or higher (vs N0) disease and the probability of (D) N2 or N3 (vs N0 or N1) disease by
decile of expected risk for patients that met inclusion criteria from non-MDACC institutions that had more than 50 eligible patients (n ¼ 1,146). The
observed probability for each decile is on the vertical axis; the predicted probability for each decile is on the horizontal axis. A perfect model, where
observed ¼ predicted, is shown by the line. HOMER ¼ Help with Oncologic Mediastinal Evaluation for Radiation; MDACC ¼ MD Anderson Cancer
Center.

outperform the baseline HOMER model (P < .001 for
predicting prN1j2j3 [vs N0] disease and P < .001 for
predicting prN2j3 [vs N0j1] disease), the absolute
magnitude of discrimination improvement was small
(ROC-AUC improved from 0.837 to 0.854 for predicting
prN1j2j3 [vs N0] disease and from 0.876 to 0.891 for
predicting prN2j3 [vs N0j1] disease).
Details of the exploratory analysis comparing the
previously published institution-speciﬁc calibrated
models are summarized in e-Table 7. The baseline
HOMER model outperformed the institution-speciﬁc
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calibrated HOMER models in every institution (eAppendix 1).

Discussion
In this study, we prospectively and externally validated
the HOMER and HAL models, which estimate the
probability of metastatic nodal disease in NSCLC
patients as determined by EBUS-TBNA. We found that
both models performed well in multiple outside
institutions. External validation conﬁrmed good
discrimination. Although the Hosmer-Lemeshow test
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TABLE 4

] HOMER Model Performance at Different Institutions
ROC-AUC prN1|2|3
(95% CI)

ROC-AUC prN2|3
(95% CI)

Brier
Score

Observed prN1|2|3
(vs N0)

Forecast prN1|2|3
(vs N0)

Observed prN2|3
(vs N0|1)

Forecast prN2|3
(vs N0|1)

HL P

Entire non-MDACC
cohort (n ¼ 1,244)

0.837 (0.814-0.859)

0.876 (0.855-0.897)

0.349

0.357

0.339

0.259

0.261

.002

Non-MDACC data
excluding centers
with <50 patients
(n ¼ 1,146)

0.837 (0.813-0.860)

0.878 (0.86-0.900)

0.341

0.335

0.325

0.233

0.249

<.001

Cleveland Clinic
Foundationa (n ¼ 308)

0.851 (0.803-0.912)

0.912 (0.879-0.945)

0.283

0.263

0.290

0.182

0.218

.098

Henry Ford Hospitala
(n ¼ 108)

0.812 (0.729-0.897)

0.849 (0.773-0.924)

0.345

0.389

0.361

0.269

0.289

.008

Johns Hopkinsa (n ¼ 193)

0.803 (0.739-0.867)

0.838 (0.777-0.900)

0.363

0.363

0.380

0.285

0.302

.038

Royal Melbourne
Hospitalb (n ¼ 133)

0.878 (0.819-0.938)

0.919 (0.864-0.974)

0.370

0.504

0.402

0.338

0.288

.027

Michael E. DeBakey VAb
(n ¼ 117)

0.912 (0.857-0.966)

0.911 (0.845-0.978)

0.263

0.265

0.208

0.188

0.169

.148

St. Luke’s of Kansas
Cityb (n ¼ 102)

0.867 (0.798-0.937)

0.887 (0.813-0.962)

0.332

0.333

0.276

0.245

0.205

.354

Population
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VA Portlandb (n ¼ 54)

0.886 (0.786-0.985)

0.911 (0.832-0.990)

NA

NA

NA

NA

NA

NA

Stanford Universityb
(n ¼ 64)

0.711 (0.581-0.841)

0.834 (0.736-0.932)

NA

NA

NA

NA

NA

NA

University of Chicagob
(n ¼ 67)

0.672 (0.535-0.809)

0.809 (0.691-0.927)

NA

NA

NA

NA

NA

NA

Brier scores range from 0 (perfect) to 2 (worst) when there are three possible outcomes, so the interpretation is different for HOMER and HAL. The lower Brier scores in HAL do not imply the HAL is better than HOMER.
H-L ¼ Hosmer-Lemeshow; MDACC ¼ MD Anderson Cancer Center; N0|1 ¼ N0 or N1; NA ¼ not applicable because enrollment did not reach the required n $ 100 for these centers; prN1|2|3 ¼ probability of N1 disease
or higher; prN2|3 ¼ probability of N2 or N3 disease; ROC-AUC ¼ area under the receiver operator characteristic curve.
a
Hospital where HOMER was previously validated, new data here tests temporal external validation of HOMER.
b
Hospital where HOMER was never tested before, external validation of HOMER.

]

suggested some calibration error beyond random
variation, the calibration error was small and not evident
as assessed by observed vs predicted plots and Brier
scores.27 The forecast vs observed probabilities of disease
for HAL (25.1% vs 23.9% for N2j3) and HOMER
(33.9% vs 35.7% for N1j2j3 and 26.1% vs 25.9% for
N2j3) suggest that HAL slightly overestimates the
prN2j3 disease, whereas HOMER overestimates the
prN0 disease.
Graphically this means that the curve in the observed
vs predicted plots for HAL (Fig 2) is slightly but
statistically signiﬁcantly shifted to the right of the perfect
prediction line. For HOMER, in the plot of prN1j2j3 (vs
N0) disease (Fig 4A), the curve is shifted slightly to the
left. This shift is a representation of the HosmerLemeshow goodness-of-ﬁt test, which tests overall
calibration error. However, the absolute magnitude of
the shift is small, as reﬂected in the difference between
forecast and observed probabilities (þ1.2% difference
for HAL and 1.8% and þ0.2% for HOMER for
prN1j2j3 and prN2j3, respectively. Therefore, the data
suggest that although calibration error is present, the
magnitude of the difference is relatively modest, such
that the models are informative.27
How well clinical prediction models perform over
extended periods is important if they are to be used in
everyday practice. The original HAL model10 used data
from 2009, and the last patients in this study were from
2019. Both HAL and HOMER demonstrate good
discrimination and calibration over a 10-year period at
the four centers that performed both studies, providing
evidence of temporal validation and stability over time.
Improving decision-making during the evaluation of
lung cancer is fundamental to improve the value of
patient care.28 ACCP and NCCN guidelines suggest that
mediastinal lymph node sampling with EBUS be
performed as the ﬁrst invasive test in patients with
sufﬁciently high probability of nodal disease. Inaccurate
estimates of the probability of nodal disease can in turn
lead to ineffective staging. For example, examination of
SEER-Medicare data from 2004 to 2013 shows that only
23% to 34% of patients with lung cancer stage T1-3, N13, M0 disease received mediastinal sampling as part of
their ﬁrst invasive test, as recommended by guidelines.29
Instead of guideline-consistent care, most patients had a
biopsy of the peripheral nodule or mass ﬁrst, usually
using a percutaneous CT-guided approach. Mediastinal
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sampling was delayed and sometimes never done.
Unfortunately, this guideline-inconsistent pattern of
care led to more biopsies and more complications. One
factor contributing to this quality gap in cancer care is
the difﬁculty in quantifying the probability of
mediastinal and hilar nodal involvement.
Clinical prediction rules such as HAL and HOMER can
help address this problem by better informing providers
as to the probability of nodal involvement. HAL and
HOMER demonstrated adequate discrimination and
fairly good calibration. We believe that on balance HAL
and HOMER remain informative and can improve
decision-making during the evaluation of lung cancer
analogous to the VA and Mayo models for SPNs.
HAL and HOMER can also inform decisions in
scenarios in which the guidelines’ recommendations for
the next step in management is not clear, such as
determining whether a PET-scan is required after CT
staging when EBUS is being considered, whether
performing EBUS-TBNA is warranted after PET-CT
imaging is done, and whether conﬁrmatory
mediastinoscopy after a negative EBUS-TBNA is
required.1,2,4,8,10,17 For example, consider a 60-year-old
patient with a peripherally located, CT N0 stage
adenocarcinoma. Should this patient have a PET scan?
According to HOMER, the prN1 ranges from 1.5% to
3.9% and a prN2j3 of 5.2% to 36.6%, depending on the
PET N stage. The European Society of Thoracic Surgery
(ESTS) suggests that proceeding to thoracotomy is
reasonable, provided the probability of ﬁnding N2j3
disease at the time of surgery is less than 10%.30 A PET
scan would be useful in this patient, because a PET N0
result would lead to surgery (prN2j3 < 10% threshold),
whereas a PET showing nodal uptake would change
management to EBUS (prN2j3 >10% threshold).
Conversely, if a patient instead had CT N2 disease, the
prN1 ranges from 4.6% to 6.0%, and the prN2j3 ranges
from 12.7% to 69.8%, depending on the PET N stage. In
this case, we see that regardless of the PET N stage, the
lowest the prN2j3 will be is 12.7%, which is higher than
the suggested ESTS 10% threshold.30 Therefore, EBUS
sampling in this case will be warranted no matter what,
so proceeding directly to EBUS rather than waiting for a
PET scan is warranted. In both patients, calculating the
range of probabilities is useful.
The second decision that HOMER can inform is
determining whether EBUS should be done.17 For
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instance, consider two cases in which SABR is a
treatment option. In the ﬁrst case (A), a 60-year-old
patient with a peripheral undifferentiated NSCLC, PETCT N0, who is surgically ﬁt but prefers SABR, is
evaluated. HOMER predicts a 93% prN0 disease. In the
second case (B), an 80-year-old patient with severe
COPD who cannot tolerate lobectomy has a peripheral
squamous cell carcinoma PET-CT N0. HOMER predicts
a 98% prN0 disease. In both cases, ﬁnding N2 disease
would lead to multimodal chemoradiation over SABR.
However, in case A, ﬁnding N1 disease leads to surgery,
whereas in case B it leads to deﬁnitive radiation therapy
(alone or with chemotherapy).8,17 In case A, when
weighing the risk of complications at approximately
1.15%31 vs the probability of occult nodal involvement at
7%, EBUS seems warranted because nodal involvement
will change treatment from SABR to surgery with
adjuvant chemotherapy or chemoradiation. Conversely,
in case B, where there is only a 2% probability of ﬁnding
malignant nodal disease vs a 1.15% risk of
complications,31 proceeding directly to SABR seems
reasonable.17 Although the absolute difference in
probability of occult nodal metastasis between the two
scenarios is small (2% vs 7%), the decision context is
complex and involves consideration of the probability of
EBUS being positive.
The third decision the models inform is whether
conﬁrmatory mediastinoscopy is warranted in
patients that have a negative EBUS.10 Guidelines
recommend that if EBUS is negative for malignancy
in the N2j3 nodes but the suspicion of mediastinal
nodal involvement remains high, mediastinoscopy be
performed.8 But the guidelines do not identify which
patients with a negative EBUS are high risk for nodal
disease and which patients have a sufﬁciently low
risk that proceeding directly to lobectomy is
warranted. HAL can inform this decision. Because we
know the sensitivity and speciﬁcity of EBUS, HAL
can be used to approximate the pretest prN2j3
disease that can, in turn, be used to estimate the
posterior probability of N2j3 disease given a negative
EBUS (see e-Appendix 1 for details). The posterior
probability of N2j3 disease then informs the decision
on whether a conﬁrmatory mediastinoscopy is
necessary; if it is less than the surgical decision
threshold (eg, ESTS threshold of 10%), then
proceeding directly to lobectomy is warranted,
whereas if it is greater than the decision threshold
probability, conﬁrmatory mediastinoscopy is
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warranted.10,30 HAL and HOMER do not dictate
what the surgical decision threshold probability or
what the next step in management is, but merely
inform and improve the decision process.
HAL and HOMER also reﬁne and challenge existing
paradigms with large lesions (>3cm) that are PET-CT
N0. The ACCP lung cancer guidelines recommend that
for patients with a peripheral clinical stage IA tumor
(PET-CT N0), invasive preoperative evaluation of the
mediastinal node is not required (Grade 2B).1 The
ACCP guidelines remain silent on whether peripheral
tumors > 3 cm that are PET-CT N0 should have
invasive preoperative evaluation of the mediastinal
nodes. However, indirectly they imply that it would be
reasonable to do mediastinal staging in such lesions.
Similarly, the NCCN guidelines do recommend that
patients with tumors > 3 cm that are PET-CT N0
undergo invasive preoperative evaluation of the
mediastinal nodes.8 However, HAL and HOMER
suggest that the probability of malignant nodal disease
in patients with PET-CT N0 disease is low enough that
foregoing EBUS-TBNA would be reasonable even when
the tumor is large. Indeed, in this study, among 198
patients with peripheral lesions measuring >3 cm who
were PET-CT N0, only two (1.0%; 95% CI, 0.1%-3.6%;
e-Table 8) had N2j3 disease by EBUS. Note that the
upper bound of the 95% credible interval of the
proportion of patients having N2j3 disease by EBUS is
signiﬁcantly less than the 10% surgical threshold
suggested by the ESTS (P < .001, binomial exact test).30
Therefore, although the guidelines indirectly suggest that
patients with tumors measuring > 3 cm warrant EBUS,
our data suggest that foregoing EBUS in select cases
might be reasonable.
This study is the ﬁrst multicenter prospective external
and temporal validation of a clinical prediction model
for mediastinal and hilar nodal involvement as
determined by EBUS. Future studies will be needed to
test the utility of the models and determine whether they
impact care. Integration of HAL and HOMER into
electronic decision aids may facilitate these endeavors. A
webpage is now available that can be used to calculate
nodal metastasis probabilities using HOMER,32 and
prediction tables are in e-Tables 9 and 10.
However, although HAL and HOMER have both been
shown to have overall good performance, it is important to
acknowledge their limitations, especially as applied to
clinical practice. First, HAL and HOMER demonstrated
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some calibration issue in one institution (The Royal
Melbourne Hospital). Also, performance might vary
signiﬁcantly in other settings if the type of EBUS staging
procedure were changed. In this study, all patients had
systematic staging, with sampling of all lymph nodes
measuring $ 5 mm by EBUS. If this were changed, HAL
and HOMER might not perform as well. In addition, HAL
and HOMER predict EBUS results, and EBUS has
limitations in terms of its sensitivity,33 which must be
accounted for as previously described.10,17 Finally, HAL and
HOMER are dependent on the cytopathologist interpreting
the samples. If there is signiﬁcant variability between centers
in terms of specimen handling or cytopathologist
interpretation, this will impact model performance.
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Interpretation
In summary, we found that both HAL and HOMER
performed well across multiple institutions in terms of
their ability to predict mediastinal and hilar lymph node
metastasis as identiﬁed by EBUS. The data provide
external validation as well as temporal validation for the
models. Discrimination and calibration were good, as
assessed by observed vs predicted plots and Brier scores.
The Hosmer-Lemeshow test suggested some degree of
calibration error. The magnitude of the calibration error
was small, such that the models are acceptable for
clinical use.27 Future studies will need to assess their
utility and hopefully use these models to improve lung
cancer care.
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